Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and feasibility of the following
two regimens: Cohort A) phased regimen of pembrolizumab in which paclitaxel is followed by
paclitaxel plus pembrolizumab and Cohort B) concurrent regimen of paclitaxel plus
pembrolizumab. The primary safety objective is to evaluate the overall grade 3 or 4
treatment-related adverse event rate for each cohort and compare them to relevant historical
controls.